Alderuccio JP, Sharman JP. ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. Blood Rev 2022;[Online ahead of print]. Abstract
Allan JN et al. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 2022;107(4):984-7. Abstract
Al-Sawaf O et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 2021;39(36):4049-60. Abstract
Al-Sawaf O et al. Should undetectable minimal residual disease be the goal of chronic lymphocytic leukemia therapy? Hematol Oncol Clin North Am 2021;35(4):775-91. Abstract
Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study. EHA 2022;Abstract S146.
Brown JP et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients. Haematologica 2022;107(6):1335-46. Abstract
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Davids MS et al. Majic: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. ASH 2021;Abstract 1553.
Eichhorst B et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: First co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. ASH 2021;Abstract 71.
Flinn IW et al. Debulking before initiation of venetoclax therapy in untreated patients with chronic lymphocytic leukemia: Results from a phase 3b study. ASH 2021;Abstract 3725.
Ghia P et al. First-line treatment with ibrutinib (ibr) plus venetoclax (ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 captivate study. ASH 2021;Abstract 68.
Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LBA1900.
Hillmen P et al. Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. ASH 2021;Abstract 642.
Hillmen P et al. The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: The results of the planned interim analysis of the phase III NCRI Flair trial. EHA 2022;Abstract S145.
Jacobs R et al. Efficacy and safety of ublituximab in combination with umbralisib (U2) in patients with chronic lymphocytic leukemia (CLL) by treatment status: A sub-analysis of the phase 3 Unity-CLL study. ASH 2021;Abstract 3726.
Jurczak W et al. Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up. ASCO 2022;Abstract 7538.
Kater A et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.
Kater AP et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence, May 13,2022. Abstract
Kater AP et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): Primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 2022;23(6):818-28. Abstract
Ma S et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. Blood 2021;138(10):836-46. Abstract
Mato AR et al. A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib. Haematol 2022;[Online ahead of print]. Abstract
Mato AR et al. Pirtobrutinib (LOXO-305), a highly selective, non-covalent BTK inhibitor in previously treated Richter transformation: Updated results from the phase 1/2 BRUIN study. EHA 2022;Abstract EP524.
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391.
Mato AR et al. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: Post-hoc analyses from the phase III MURANO study. Haematol 2022;107(1):134-42. Abstract
Melenhorst JJ et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022;602(7897):503-9. Abstract
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: The GLOW study. ASH 2021;Abstract 70.
O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11:720704. Abstract
Rogers KA et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Hameatologica 2021;106(9):2364-73. Abstract
Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020;5(48):eabd0110. Abstract
Seymour JF et al. Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 3721.
Shadman M et al. Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib. ASCO 2021;Abstract e19506.
Shanafelt TD et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood 2022;[Online ahead of print]. Abstract
Sharma S et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). ASH 2021;Abstract 4365.
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Sharman JP et al. BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress). ASH 2021;Abstract 3736.
Sharman JP et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leuk 2022;36(4):1171-5. Abstract
Sharman JP et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): A phase 3, multicentre, open-label, randomised trial. Lancet Haematol 2021;8(4):e254-66. Abstract
Siddiqi T et al. Phase 1 TRANSCENT CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 2021;139(12):1794-806. Abstract
Solman I et al. Immune restoration and synergistic activity with first-line (1l) ibrutinib (ibr) plus venetoclax (ven): Translational analyses of CAPTIVATE patients with CLL. EHA 2022;Abstract S144.
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituzimab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396.
Thompson MC et al. All in the family: Back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia. Hameatol 2021;106(9):2300-1. Abstract
Wang E et al. Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors. N Engl J Med 2022;386(8):735-43. Abstract
Wierda WG et al. Fixed-duration (FD) ibrutinib (i) + venetoclax (v) for first-line treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. ASCO 2022;Abstract 7519.